38 related articles for article (PubMed ID: 18163548)
1. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
[TBL] [Abstract][Full Text] [Related]
2. Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases.
Jiang L; Zhang X; Zhou Y; Chen Y; Luo Z; Li J; Yuan C; Huang M
RSC Adv; 2018 Aug; 8(49):28189-28197. PubMed ID: 35542712
[TBL] [Abstract][Full Text] [Related]
3. Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.
El Salamouni NS; Buckley BJ; Ranson M; Kelso MJ; Yu H
Biophys Rev; 2022 Feb; 14(1):277-301. PubMed ID: 35340592
[TBL] [Abstract][Full Text] [Related]
4. Bioisosteric Modification of To042: Synthesis and Evaluation of Promising Use-Dependent Inhibitors of Voltage-Gated Sodium Channels.
Milani G; Cavalluzzi MM; Altamura C; Santoro A; Perrone M; Muraglia M; Colabufo NA; Corbo F; Casalino E; Franchini C; Pisano I; Desaphy JF; Carrieri A; Carocci A; Lentini G
ChemMedChem; 2021 Dec; 16(23):3588-3599. PubMed ID: 34519427
[TBL] [Abstract][Full Text] [Related]
5. Fragment-based drug discovery: opportunities for organic synthesis.
St Denis JD; Hall RJ; Murray CW; Heightman TD; Rees DC
RSC Med Chem; 2020 Dec; 12(3):321-329. PubMed ID: 34041484
[TBL] [Abstract][Full Text] [Related]
6. Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2.
Huggins DJ
J Mol Graph Model; 2020 Nov; 100():107710. PubMed ID: 32829149
[TBL] [Abstract][Full Text] [Related]
7. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Buckley BJ; Aboelela A; Minaei E; Jiang LX; Xu Z; Ali U; Fildes K; Cheung CY; Cook SM; Johnson DC; Bachovchin DA; Cook GM; Apte M; Huang M; Ranson M; Kelso MJ
J Med Chem; 2018 Sep; 61(18):8299-8320. PubMed ID: 30130401
[TBL] [Abstract][Full Text] [Related]
8. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
[TBL] [Abstract][Full Text] [Related]
9. Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery.
Hall DR; Kozakov D; Whitty A; Vajda S
Trends Pharmacol Sci; 2015 Nov; 36(11):724-736. PubMed ID: 26538314
[TBL] [Abstract][Full Text] [Related]
10. Application of molecular modeling to urokinase inhibitors development.
Sulimov VB; Katkova EV; Oferkin IV; Sulimov AV; Romanov AN; Roschin AI; Beloglazova IB; Plekhanova OS; Tkachuk VA; Sadovnichiy VA
Biomed Res Int; 2014; 2014():625176. PubMed ID: 24967388
[TBL] [Abstract][Full Text] [Related]
11. Structural characterization and inhibition of the Plasmodium Atg8-Atg3 interaction.
Hain AU; Weltzer RR; Hammond H; Jayabalasingham B; Dinglasan RR; Graham DR; Colquhoun DR; Coppens I; Bosch J
J Struct Biol; 2012 Dec; 180(3):551-62. PubMed ID: 22982544
[TBL] [Abstract][Full Text] [Related]
12. Hit clustering can improve virtual fragment screening: CDK2 and PARP1 case studies.
Zeifman AA; Stroylov VS; Novikov FN; Stroganov OV; Zakharenko AL; Khodyreva SN; Lavrik OI; Chilov GG
J Mol Model; 2012 Jun; 18(6):2553-66. PubMed ID: 22069029
[TBL] [Abstract][Full Text] [Related]
13. The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.
Nowicki TS; Moscatello AL; Shin E; Schantz S; Tiwari RK; Geliebter J
J Clin Endocrinol Metab; 2011 Oct; 96(10):3062-4. PubMed ID: 21832115
[No Abstract] [Full Text] [Related]
14. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
Frederickson M; Callaghan O; Chessari G; Congreve M; Cowan SR; Matthews JE; McMenamin R; Smith DM; Vinković M; Wallis NG
J Med Chem; 2008 Jan; 51(2):183-6. PubMed ID: 18163548
[TBL] [Abstract][Full Text] [Related]
15. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
[TBL] [Abstract][Full Text] [Related]
16. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
Joossens J; Van der Veken P; Surpateanu G; Lambeir AM; El-Sayed I; Ali OM; Augustyns K; Haemers A
J Med Chem; 2006 Sep; 49(19):5785-93. PubMed ID: 16970403
[TBL] [Abstract][Full Text] [Related]
17. Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines.
Fish PV; Barber CG; Brown DG; Butt R; Collis MG; Dickinson RP; Henry BT; Horne VA; Huggins JP; King E; O'Gara M; McCleverty D; McIntosh F; Phillips C; Webster R
J Med Chem; 2007 May; 50(10):2341-51. PubMed ID: 17447747
[TBL] [Abstract][Full Text] [Related]
18. Does the urokinase receptor exist in a latent form?
Yuan C; Huang M
Cell Mol Life Sci; 2007 May; 64(9):1033-7. PubMed ID: 17372678
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
